BPC-157 vs TB-500: which one should I pick?
BPC-157 if your injury is tendon, ligament, or gut. TB-500 if it's soft tissue (muscle tear, joint capsule). Stacking both is the community default but the human evidence does not support it; you double the unknowns without doubling the proven benefit. Pick one, run a 4 to 6 week cycle, evaluate.
Last reviewed · Panya.health editorial
Mechanism overlap is real
BPC-157 was isolated from human gastric juice and shows effects on angiogenesis (new blood vessel formation), tendon-to-bone healing, gut barrier integrity, and possibly nitric oxide pathways. TB-500 (a synthetic fragment of thymosin beta-4) shows effects on actin sequestration, cell migration to injury sites, and matrix remodelling. Both ultimately drive 'cells get to the injury and rebuild,' just via different upstream mechanisms. The community treats them as additive; the rodent literature does not directly compare them in head-to-head trials, so the additive case is theoretical.
Pick one based on the injury
Tendon, ligament, or gut: BPC-157 has more rodent + small Phase 2 work in those tissues (Chang 2014 J Orthop Res for tendon-to-bone). Skeletal muscle, joint capsule, or post-surgical soft-tissue recovery: TB-500 has more cardiac and corneal wound-healing data and the actin-sequestration mechanism reads more directly applicable. Cycle dose for either: 250 to 500 mcg/day for BPC-157, or 2 to 2.5 mg twice weekly for TB-500. Run for 4 to 6 weeks, stop, evaluate at week 8.
Why stacking is overrated
Three reasons. First, neither has human-validated dosing, so stacking compounds dose-uncertainty rather than adding precision. Second, both promote angiogenesis, which is the same downstream concern (cancer-pathway interaction). You don't reduce that risk by stacking. Third, if you stack and respond well, you don't know which one helped; if you respond poorly, you don't know which to drop. Single-compound trials at the personal level give you actionable signal. Both compounds are also banned under WADA's S0 (BPC-157, 2024 list) and TB-500's bans for competitive athletes; if you compete, either one is a problem.
Where Panya stands
Both compounds are documented at panya.health/peptide/bpc-157 and panya.health/peptide/tb-500 with full mechanism, evidence, and risk paragraphs. Panya does not yet route to vendors for either; the documentation pages list community-mentioned vendors without endorsement until the lawyer review for non-GLP-1 affiliate routing closes. The reconstitution calculator at panya.health/tools/reconstitution-calculator handles the math for both.
Related posts
The phrase on every grey-market peptide site. What it actually means, what it does not mean, and why reading it wrong costs people money.
The five things that matter on a COA, the three things that do not, and the one question that separates a serious vendor from a cargo-cult operator.
The clinic route costs more and takes longer. The research-chem route puts more on you. Neither is wrong. Here is how to choose.
People who asked this also asked
The tools behind the answer
The answer for your situation.
The answer above is the general case. The match for your specific profile, region, budget, and urgency comes from our 2-minute quiz. One email, your match, no list.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.